Evaluation of relationship between pharmacokinetics and clinical response of voriconazole.

Evaluation of relationship between pharmacokinetics and clinical response of voriconazole. - Evaluation of relationship between pharmacokinetics and clinical response of voriconazole.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000011499

Enrollment

200

Registered

2013-08-16

Start date

2009-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

immunocompromised or fungal infection

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Japanese patients receiving voriconazole more than 5 days by orally or intravenously.

Exclusion criteria

Exclusion criteria: patients (1) on dialysis; (2) who had hepatopathy (total bilirubin > 2.0 mg/dL); (3) co-treated with rifampicin, ritonavir, carbamazepine, and long-acting barbiturates; and (4) with poor compliance with respect to their medications.

Design outcomes

Primary

Measure	Time frame
The clinical response and plasma concentration of voriconazole at day 5th day or later after the initiation of treatment.	—

Countries

Japan

Contacts

Public ContactTakahiro Yamada

Hamamatsu University School of Medicine Department of Hospital Pharmacy

yamadat@hama-med.ac.jp053-435-2763

Outcome results